The latest data supporting pharmaceutical company Novartis' potential vaccine for the killer strain was revealed at the European Society for Paediatric Infectious Diseases (ESPID) in The Hague.
It shows that the vaccine, called 4CMenB, guarded against 80 per cent of the 1000 strains collected from across Europe.
The study showed the vaccine worked safely alongside other vaccines when tested on 1,800 infants across Europe.
Click "source" for entire article.
